Treatment Of Anxiety And Depression
This week we present 2 new clinical updates, both for CME. One from
Jerrold F. Rosenbaum, MD entitled, Treatment of Anxiety Disorders With
Comorbid Depression, and the other by Henry Nasrallah, MD on
Antidepressant Pharmacotherapy.
Do you know if users who aren't registered at MedScape can get these
links? When I have posted medscape links at other sites, many have
told me they cannot get to the links. That was over a year ago, so
perhaps registration is no longer required.
I have not been to the medscape site in a very long time. I do get the
newsletter, and with Lynda now gone, it is the least I can do to post the
newsletter. I appologize if the links don't work, or if you need to register
with medscape to see the articles. It appears that some can see them and some
can not! I have no clue! Maybe those who can't get the link should email
medscape?
(Assignee -- Bristol-Myers Squibb Company)
Abstract: An improved method of treatment for anxiety and/or depression
provides a quicker and more robust anxiolytic/antidepressant activity to
a patient suffering from depression.
U.S. Patents via NewsEdge Corporation : Abstract: An improved method of
treatment for anxiety and/or depression provides a quicker and more
robust anxiolytic/antidepressant activity to a patient suffering from
depression. The method comprises the concurrent administration of
effective doses of certain azapirones, such as buspirone, given in a
manner that suppresses formation of the 1-(2-pyrimidinyl)piperazine
metabolite; and a 5-HT1A autosomal receptor antagonist, such as
pindolol.
Ex Claim Text: An improved method for treating clinical anxiety and/or
depression wherein the improvement comprises concurrent administration
to an anxious and/or depressed patient of (a) an azapirone or its
pharmaceutically acceptable salt selected from the group consisting of
buspirone, gepirone, ipsapirone, tandospirone and zalospirone; with the
azapirone being administered in such a manner as to suppress formation
of the 1-pyrimidinylpiperazine metabolite, the route of administration
selected from transmucosal, transdermal, or peroral using an extended
release oral formulation; and (b) a 5-HT1A autosomal receptor antagonist
or a pharmaceutically acceptable salt thereof; resulting in a more rapid
onset of action with increased efficacy.